資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31002
|
| 標題: | Glutamate Decarboxylase 1 Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma |
| 作者: | Lee, Yi-Ying
Chao, Tung-Bo
Sheu, Ming-Jen
Tian, Yu-Feng
Chen, Tzu-Ju
Lee, Sung-Wei
He, Hong-Lin
Chang, I-Wei
Hsing, Chung-Hsi
Lin, Ching-Yih
Li, Chien-Feng |
| 貢獻者: | Chi Mei Med Ctr, Dept Pathol
Yuans Gen Hosp, Dept Colorectal Surg
Meiho Univ, Dept Hlth Business Adm
Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol
Chi Mei Med Ctr, Div Gen Surg
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Chi Mei Med Ctr, Dept Pathol
Chi Mei Med Ctr, Dept Radiat Oncol
I Shou Univ, E DA Hosp, Dept Pathol
Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol
Chang Gung Univ, Coll Med
Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management |
| 關鍵字: | GAD1
nasopharyngeal carcinoma
glutamate acid decarboxylase 1
gamma-aminobutyric acid
transcriptome
Prognosis
metastasis |
| 日期: | 2016 |
| 上傳時間: | 2018-01-18 11:39:36 (UTC+8) |
| 出版者: | Ivyspring Int Publ |
| 摘要: | Background: Glutamate decarboxylase 1 (GAD1) which serves as a rate-limiting enzyme involving in the production of.-aminobutyric acid (GABA), exists in the GABAergic neurons in the central nervous system (CNS). Little is known about the relevance of GAD1 to nasopharyngeal carcinoma (NPC). Through data mining on a data set derived from a published transcriptome database, this study first identified GAD1 as a differentially upregulated gene in NPC. We aimed to evaluate GAD1 expression and its prognostic effect on patients with early and locoregionally advanced NPC. Methods: We evaluated GAD1 immunohistochemistry and performed an H-score analysis on biopsy specimens from 124 patients with nonmetastasized NPC receiving treatment. GAD1 overexpression was defined as an H score higher than the median value. The findings of such an analysis are correlated with clinicopathological behaviors and survival rates, namely disease-specific survival (DSS), distant-metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS) rates. Results: GAD1 overexpression was significantly associated with an increase in the primary tumor status (p < 0.001) and American Joint Committee on Cancer (AJCC) stages III-IV (p = 0.002) and was a univariate predictor of adverse outcomes of DSS (p = 0.002), DMeFS (p < 0.0001), and LRFS (p = 0.001). In the multivariate comparison, in addition to advanced AJCC stages III-IV, GAD1 overexpression remained an independent prognosticator of short DSS (p = 0.004, hazard ratio = 2.234), DMeFS (p < 0.001, hazard ratio = 4.218), and LRFS (p = 0.013, hazard ratio = 2.441) rates. Conclusions: Our data reveal that GAD1 overexpression was correlated with advanced disease status and may thus be a critical prognostic indicator of poor outcomes in NPC and a potential therapeutic target to facilitate the development of effective treatment modalities. |
| 關聯: | Journal of Cancer, v.7 n.12, pp.1716-1723 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1503 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
